US a key market, have strong presence in it: Ankur Vaid, Concord Biotech

So we expect to do better than what we have done historically, which was a CAGR growth of 18%. And this as economies of scale would kick in once a new site starts ramping up, we see our margin profiling being better than what it has been historically, which has been in the range of around 40%.